Omega‐3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose‐Response Meta‐Analysis of Randomized Controlled Trials

Xin Zhang,Jennifer A. Ritonja,Na Zhou,Bingshu E. Chen,Xinzhi Li

DOI: https://doi.org/10.1161/JAHA.121.025071

2022-06-03

Abstract:Background Current evidence might support the use of omega‐3 fatty acids (preferably docosahexaenoic acid and eicosapentaenoic acid) for lowering blood pressure (BP), but the strength and shape of the dose‐response relationship remains unclear. Methods and Results This study included randomized controlled trials published before May 7, 2021, that involved participants aged ≥18 years, and examined an association between omega‐3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid, or both) and BP. A random‐effects 1‐stage cubic spline regression model was used to predict the average dose‐response association between daily omega‐3 fatty acid intake and changes in BP. We also conducted stratified analyses to examine differences by prespecified subgroups. Seventy‐one trials were included, involving 4973 individuals with a combined docosahexaenoic acid+eicosapentaenoic acid dose of 2.8 g/d (interquartile range, 1.3 g/d to 3.6 g/d). A nonlinear association was found overall or in most subgroups, depicted as J‐shaped dose‐response curves. The optimal intake in both systolic BP and diastolic BP reductions (mm Hg) were obtained by moderate doses between 2 g/d (systolic BP, −2.61 [95% CI, −3.57 to −1.65]; diastolic BP, −1.64 [95% CI, −2.29 to −0.99]) and 3 g/d (systolic BP, −2.61 [95% CI, −3.52 to −1.69]; diastolic BP, −1.80 [95% CI, −2.38 to −1.23]). Subgroup studies revealed stronger and approximately linear dose‐response relations among hypertensive, hyperlipidemic, and older populations. Conclusions This dose‐response meta‐analysis demonstrates that the optimal combined intake of omega‐3 fatty acids for BP lowering is likely between 2 g/d and 3 g/d. Doses of omega‐3 fatty acid intake above the recommended 3 g/d may be associated with additional benefits in lowering BP among groups at high risk for cardiovascular diseases. Nonstandard Abbreviations and Acronyms DBP diastolic blood pressure DHA docosahexaenoic acid EPA eicosapentaenoic acid JELIS Japan Eicosapentaenoic Acid Lipid Intervention Study REDUCE‐IT Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial SBP systolic blood pressure ω3 PUFA omega‐3 polyunsaturated fatty acid Clinical Perspective What Is New? Intake of omega‐3 fatty acids has a nonlinear association with reductions in blood pressure. The optimal daily intake of omega‐3 fatty acid for blood pressure control appears to be 3 g. What Are the Clinical Implications? An optimal dose of omega‐3 fatty acids is potentially needed for blood pressure control in the general population, but individuals who are at high risk of developing cardiovascular diseases may benefit from higher doses. Epidemiologic and experimental studies indicate that omega‐3 polyunsaturated fatty acids (ω3 PUFAs), preferably including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have cardiovascular health benefits by reducing modifiable risk factors. For example, intake of EPA was associated with reduced risks of major vascular events in JELIS (Japan Eicosapentaenoic Acid Lipid Intervention Study) 1 and REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial). 2 However, recently completed clinical studies and meta‐analyses 5 , 6 showed that supplementation of ω3 PUFAs did not offer significant favorable impacts on cardiovascular events, such as the risk of cardiovascular disease, myocardial infarction, or stroke. Previous meta‐analyses have also examined the association between ω3 PUFA intake and blood pressure (BP), 7 , 8 , 9 , 10 , 11 but have been unable to reveal a significant dose‐response relationship 8 , 10 , 12 or have shown conflicting trends. 7 , 11 These past meta‐analyses examined the dose‐response relationship using -Abstract Truncated-